Wockhardt Ltd Q1 FY2027 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/hdmcjp5ieukxi3f0gdl61ibn.pdf

Key Takeaways


ZAYNICH: The Lead Asset

Habil Khorakiwala: "there is a very high probability or certainty I would say that we should be able to market the product sometime in '26-'27."

Miqnaf: The India Launch

Murtaza Khorakiwala: "after 30 years there is a new antibiotic in the macrolide class which is there... Wockhardt has introduced India discovered, India R&D, India developed clinical trial done in India, Maa product for the Indian market which we will now take outside India into the rest of the world after 35 years"

Diabetes Biosimilars & the Novo Nordisk Opportunity


Financial Position & Cost Restructuring


EMROK & Biotech Business Development


Guidance & Commitments

CommitmentSpecificsTimeline
ZAYNICH US filingFile with USFDAComing quarter
ZAYNICH US launchMarket the product in the USSometime in FY27 (mid-next-year)
ZAYNICH India approvalDCGI approval expectedBeginning of next year; market availability mid-next year
ZAYNICH Europe/EM filingFile in H2 this year; launch in H2 next yearH2 FY27 for filing, H2 FY28 for launch
Diabetes capacity doublingDouble capacities, new facilityNext 24 months
Business growthDouble the businessNext 3 years
Biotech partnerships$30 million equivalent business to materializeNext 24 months
R&D spendContinue at USD 200-250 million or more annuallyOngoing
ZAYNICH patient reach80,000-100,000 patientsIn 3 years

Key Metrics

MetricQ1 FY27
Revenue₹3,033 cr, +5% YoY
EBITDA₹418 cr, +67% YoY
EBITDA margin14%, expanded 500 bps YoY from 9%
Net debt₹64 cr, reduced from ₹882 cr in FY22
Net debt to equity0.01%
Cash available~₹600 cr
Equity₹4,600 cr, up from ₹3,600 cr last year
R&D spend (annual run-rate)$200–250 mn, expected to continue at this level or slightly higher
India branded business growth+4% YoY
UK business growth+8% YoY
Emerging markets business growth+10% YoY
Biosimilar business growth+20% YoY
EMROK cumulative patients treated100,000
EMROK market share~10%
ZAYNICH compassionate-use lives saved51 in the last 1.5 years